Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.

Scientific reports - 15 Jun 2022

Wang Yi-Kai, Wang Ying-Wen, Lu Chia-Ling, Huang Yi-Hsiang, Hou Ming-Chih, Chang Yuh-Lih, Lee Wei-Ping, Lan Keng-Hsin

Abstract excerpt

Worsened lipid profiles were observed in chronic hepatitis C (CHC) patients during direct-acting antivirals (DAAs) treatment, among which combination drugs confounded the effect of individual ingredient on lipid. Tenofovir alafenamide (TAF) also worsened lipid profiles in HIV patients. Structural similarity between sofosbuvir (SOF) and TAF prompted us to investigate rapid increase in total cholesterol (TC) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cholesterol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Ribavirin

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 35705594
DOI: 10.1038/s41598-022-13657-5
PMCID: PMC9200852

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.PMID 35705594Read ↗

Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Metabolic changes in chronic hepatitis C patients receiving direct acting antiviralsSemantic proximity Read ↗

Effect of antiviral therapy for HCV on lipid levels.Semantic proximity Read ↗

INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?Semantic proximity Read ↗

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.Semantic proximity Read ↗

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study.Semantic proximity Read ↗

Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment.Semantic proximity Read ↗

Brief Report: Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination.Semantic proximity Read ↗

Genotype specific peripheral lipid profile changes with hepatitis C therapy.Semantic proximity Read ↗

Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins.Semantic proximity Read ↗

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects.Semantic proximity Read ↗

Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.